Adagio Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Adagio Therapeutics's estimated annual revenue is currently $17.5M per year.
- Adagio Therapeutics's estimated revenue per employee is $192,473
- Adagio Therapeutics's total funding is $466M.
Employee Data
- Adagio Therapeutics has 91 Employees.
- Adagio Therapeutics grew their employee count by -9% last year.
Adagio Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-Founder & CEO | Reveal Email/Phone |
2 | Chief Development Officer | Reveal Email/Phone |
3 | Chief Medical Officer | Reveal Email/Phone |
4 | Chief Technology and Manufacturing Officer | Reveal Email/Phone |
5 | Chief Operating Officer | Reveal Email/Phone |
6 | Co-Founder & Chief Scientific Officer | Reveal Email/Phone |
7 | Chief Commercial Officer | Reveal Email/Phone |
8 | Sr Director Talent Acquisition | Reveal Email/Phone |
9 | Associate Director, Financial Reporting & Technical Accounting | Reveal Email/Phone |
10 | Senior Regulatory Affairs Specialist | Reveal Email/Phone |
Adagio Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Adagio Therapeutics?
Adagio is developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1 and additional potentially emergent coronaviruses. We believe our antibodies will match or exceed the potency and coverage of conventional SARS-CoV-2 antibody programs and can be used as both therapeutic and durable prophylactic treatments. Our candidates are engineered using best-in-industry antibody discovery capabilities and are designed to maximize potency and duration of effect. Our portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. Our lead program is expected to enter the clinic by the end of 2020.
keywords:N/A
$466M
Total Funding
91
Number of Employees
$17.5M
Revenue (est)
-9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Adagio Therapeutics News
Adagio Therapeutics Inc (ADGI) is higher by 2.23% Tuesday In Premarket Trading. Tuesday, April 19, 2022 07:09 AM | InvestorsObserver Analysts.
Adagio Therapeutics Inc (ADGI) is down -0.84%% today. Overall Score - 40. ADGI has an Overall Score of 40. Find out what this means to you and...
WALTHAM, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company...
Adagio Therapeutics, a Waltham startup advancing COVID-19 antibody treatments, is going public Friday just over one year after it was founded. The company raised nearly $310 million by selling 18,200,000 shares for $17 each, in the middle of its expected range, and it will trade on the Nasdaq G ...
Other Companies in Waltham
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $24.6M | 91 | 12% | N/A |
#2 | $15.5M | 91 | 6% | N/A |
#3 | $26.7M | 92 | -20% | N/A |
#4 | $18.5M | 92 | 7% | N/A |
#5 | $16.1M | 95 | -10% | $233M |